Vrouenraets B C, Peterse J L, van Dongen J A
Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam.
Neth J Surg. 1991 Jun;43(3):51-5.
Clinicopathologic features were retrospectively studied in 42 patients with ductal carcinoma in situ (DCIS), who underwent breast-conserving therapy at the Netherlands Cancer Institute from 1974 to 1987. During follow-up (13 to 128 months, average 73 months) five of the 14 patients treated with an excision alone recurred locally. Recurrence occurred in only one out of 28 patients who received additional radiotherapy. Secondary mastectomy was performed in five patients with recurrence, all are alive with no evidence of disease (average follow-up 21 months). One patient developed disseminated disease. Breast-conserving therapy might be considered in selected cases of DCIS with a limited extent, when a complete excision can be accomplished. Additional radiotherapy may reduce the risk of recurrence. Because most series in literature are small, retrospective, selected and with a short follow-up randomized prospective trials have to demonstrate what subset of patients with DCIS can safely be treated with breast-conserving therapy. Therefore, participation in these studies, is of the utmost importance.
对1974年至1987年在荷兰癌症研究所接受保乳治疗的42例导管原位癌(DCIS)患者的临床病理特征进行了回顾性研究。在随访期间(13至128个月,平均73个月),14例仅接受切除治疗的患者中有5例出现局部复发。在接受额外放疗的28例患者中,只有1例复发。5例复发患者接受了二次乳房切除术,所有患者均存活且无疾病证据(平均随访21个月)。1例患者出现播散性疾病。对于病变范围有限、能够完整切除的DCIS特定病例,可考虑保乳治疗。额外放疗可能会降低复发风险。由于文献中的大多数系列研究样本量小、属于回顾性研究、有选择性且随访时间短,因此必须通过随机前瞻性试验来证明哪些DCIS患者亚组可以安全地接受保乳治疗。因此,参与这些研究至关重要。